EBMT 2019 | Hospital exemption: enabling patients’ access to advanced therapies in the EU

Valentín Ortiz-Maldonado

Advancements in biomedical sciences are leading to novel treatment options for the treatment of hematological malignancies. Despite the promising development activity in the Advanced Therapy Medicinal Product (ATMP) field, the number of ATMPs currently available in the European market remains limited due to high regulatory demands. Valentín Ortiz-Maldonado, MD, of Hospital Clinic of Barcelona, Barcelona, Spain, mentions that applying a hospital exemption can significantly accelerate cancer patients’ access to advanced therapies, and ultimately increase their survival chances. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Share this video